Analyst Price Target is $6.00
▲ +292.16% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for AEON Biopharma in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 292.16% upside from the last price of $1.53.
Current Consensus is
Buy
The current consensus among 1 contributing investment analysts is to buy stock in AEON Biopharma. This Buy consensus rating has held steady for over two years.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.
Read More